Regeneron Pharmaceuticals Inc (REGN)

Return on assets (ROA)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	3,953,600	4,338,400	8,075,300	3,513,200	2,115,800
Total assets	US$ in thousands	33,080,200	29,214,500	25,434,800	17,163,300	14,805,200
ROA		11.95%	14.85%	31.75%	20.47%	14.29%

December 31, 2023 calculation

ROA = Net income ÷ Total assets
= $3,953,600K ÷ $33,080,200K
= 11.95%

Regeneron Pharmaceuticals, Inc.'s return on assets (ROA) has shown fluctuating trends over the past five years. The ROA was highest in 2021 at 31.75% and significantly dropped in 2023 to 11.95%. This decrease indicates a decline in the company's efficiency in generating profit from its assets in the most recent year.

Although the ROA decreased in 2023, it is still higher than the ROA of 2019 and 2020. This suggests that the company has historically been able to effectively utilize its assets to generate profits, with the 2023 level indicating a potential temporary setback.

Overall, Regeneron Pharmaceuticals, Inc. should closely monitor its asset management strategies and operational efficiency to improve its ROA and ensure sustained profitability in the future.